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Most individuals with AAT deficiency have escaped detection by healthcare systems worldwide. The large number
of undiagnosed individuals has made it dicult to define the natural history of the clinical disease accurately, and
severe ascertainment bias has colored the clinical descriptions of the disease. Most importantly, undetected
individuals lose opportunities for important lifestyle changes and preventive therapies. To address this problem, the
World Health Organization has recommended that all patients with chronic obstructive lung disease, and all adults
and adolescents with asthma, be tested for AAT deficiency. Historically, the AAT Deficiency Detection Center has
tested more than 30 000 individuals for the disease, and we have identified more than 1000 cases of AAT deficiency
(approximately 30% of the known cases in the United States). Currently, we are implementing methods for
determining AAT concentration (level), phenotype, and genotype in specimens of whole blood dried onto filter
paper. This full spectrum of robust tests is performed on samples that are easily obtained and shipped to a central
laboratory for processing. Wide application of these procedures may help to bring large numbers of presently
undiagnosed patients to medical attention.
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Despite the fact that more than 25 years have elapsed since
the discovery of AAT deficiency, most individuals with the
disease world-wide remain undiagnosed. Sweden, Denmark
and the Netherlands historically have led the rest of the
world in diagnosing AAT deficiency because of medical
interest in the disease in those countries, coupled with
healthcare systems that facilitate organized diagnostic
testing. Other countries have lagged far behind in their
eorts to diagnose aected individuals. In the United
States, for example, it is thought that fewer than 4000 cases
of AAT deficiency have been diagnosed from the estimated
100 000 individuals with the disease. Experience in the
United Kingdom has been similar (1).
Individuals who have AAT deficiency, but who have not
yet been diagnosed, are losing opportunities for important
lifestyle changes and therapies to prevent the onset or
progression of lung disease. Further, the large number of
undiagnosed individuals has made it dicult to define the
natural history of the disease, since the health status of such
individuals is largely unknown. The existing clinical reportsCorrespondence should be addressed to: Edward J. Campbell, MD,
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0954-6111/00/0C00S18+04 $35?00/0of AAT deficiency are colored by severe ascertainment bias,
since most of the individuals reported have been diagnosed
because of extant lung disease (2).
Methods for unequivocal diagnosis of AAT deficiency
have been available since the early 1960s. Thus, the limiting
factor in detecting undiagnosed patients is simply the
ordering and performing of requisite diagnostic tests. Since
this is a genetic disease, testing need be performed only once
in a lifetime. The World Health Organization has recog-
nized that many individuals with AAT deficiency may be
seeing healthcare providers, yet have been given other
diagnoses. The WHO addressed this problem with a pivotal
recommendation that all individuals with chronic obstruc-
tive lung disease, and all adults and adolescents with
asthma, be tested for the disease (3). The AAT Deficiency
Detection Center has been striving to improve compliance
with this recommendation by enhancing the convenience of
testing procedures and improving access to testing facilities.
The AAT Deficiency Detection Center
We estimate that the AAT Deficiency Detection Center in
Salt Lake City, UT, U.S.A, performs about 25% of the
testing for this disease in the United States. In the 9 years of
operation between 1 March 1991, and 29 February 2000 we
have tested 30 631 blood samples for AAT deficiency,
and have diagnosed 1021 individuals with the disease. The# 2000 HARCOURT PUBLISHERS LTD
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duals in the United States. Interestingly, 3?3% of all of the
samples that we have received during this period came from
individuals with AAT deficiency. Thus, the diagnostic yield
of blood samples sent to our laboratory exceeds that for
routine screening laboratory tests such as complete blood
counts, thyroid tests, chemistry panels and urinalyses (4).
Types of diagnostic tests for AAT
deficiency
Diagnostic testing for AAT deficiency can be divided into
four stages of tests, which are shown in Table 1. Table 1
shows the diagnostic usefulness of each type of diagnostic
test, as well as where each fits into the diagnostic spectrum
of testing for the disease. In the past, serum protein
electrophoresis was considered to be a useful diagnostic test
for the disease, in that visually-determined absence of the a-
band was an excellent correlate of AAT deficiency. This test
is not shown in Table 1, since its utility has been largely
superceded by specific immunoassays. However, AAT
deficiency is incidentally detected on occasion when a
serum protein electrophoresis is performed for an unrelated
reason.
Immunoassay is the stage 1 test for the diagnosis of AAT
deficiency. Several are available, and all are useful for
diagnosis of the disease. An immunoassay is typically the
first test that is performed when an individual is suspected
of having AAT deficiency. It measures the concentration
(‘level’) of AAT in plasma or serum. In our hands, the
reference concentration of AAT in plasma is 32?4 mM; AAT
levels of 511 mM are considered to be diagnostic of AAT
deficiency. Most individuals with AAT deficiency have
plasma levels in the range of 10–15% of normal [mean level
in our laboratory, 4?3+ (SD) 1?7 mM, n=927]. Hetero-TABLE 1
Stage of
testing
Name of test Parameter measured
I Immunoassay Concentration (‘level’)
of AAT protein in
plasma or serum
II Phenotype Isoelectric points of
AAT isoforms
III
Genotype DNA abnormality,
determined by polymerase
chain reaction
IV
Function Inhibition of leukocyte
elastasezygotes (carriers) of AAT deficiency tend to have inter-
mediate AAT levels. However, there is a substantial overlap
in AAT levels between normal individuals and hetero-
zygotes for AAT deficiency. The strengths of immunoassay
are that it is reliable, inexpensive and subject to automa-
tion. Because of the overlap in AAT levels between normals
and carriers, immunoassays suer from the weakness that
they cannot reliably detect carriers for the disease, and of
course they do not define the genetic makeup of the
individual who is being tested.
Phenotyping is the stage 2 test for AAT deficiency. It
characterizes the type(s) of AAT protein found in plasma or
serum. This is most commonly accomplished by isoelectric
focusing of plasma or serum proteins in a polyacrylamide
gel over a narrow pH range (in our laboratory, pH 4?2–
4?9). In 1979, isoelectric focusing was improved by the
addition of a reducing agent, which reduced the back-
ground staining of the gels and enhanced our ability to
recognize abnormal AAT variants (5). The major strength
of phenotyping is that it provides independent confirmation
of this critically-important diagnosis. In view of this fact,
the WHO has recommended that individuals who have
abnormal immunoassay results should subsequently under-
go phenotyping (3). This is important because the diagnosis
of AAT deficiency makes a lifelong impact on patients’
healthcare. Phenotyping also detects and identifies unusual
a1-antitrypsin alleles and identifies heterozygous for a1-
antitrypsin deficiency. Phenotyping of the most common
AAT variants is illustrated in Fig. 1. Weaknesses of
phenotyping are that it is a labor-intensive manual test
and considerable experience and expertise are required to
interpret the results. Phenotyping results are confusing in
patients who are receiving augmentation therapy, since it
detects both the infused protein as well as the patients’
native a1-antitrypsin. Further, it cannot detect the presence
of ‘null’ AAT genes that do not result in detectable AAT inStrengths Weaknesses
Relatively inexpensive
Readily automated
Does not reliably
detect heterozygotes
Independent confirmation
of diagnosis
Identifies heterozygotes
Manual technique
Requires skill and
experience
Does not detect
null alleles
Definitive
Conclusively identifies
specific mutations
Detects null alleles
Can be expensive
Requires specific
primers for each allele
May be useful if
stages I–III are
normal in suspicious cases
Little clinical
experience
with its use
S20 E. J. CAMPBELLthe plasma. Individuals who carry such genes can be
indentified only through careful family studies or by
genotyping. Rare variants may dier minimally in their
isoelectric points, leading to diculty in interpretation of
the results and the need for many standards. Standards forFIG. 1. Phenotyping of a1-antitrypsin. Five microliters of
plasma from individuals carrying the normal (M) and
most common deficient (Z) alleles was applied to lanes of
a polyacrylamide isoelectric focusing gel. After
completion of the isoelectric focusing, the proteins in the
gel were stained with Coomassie blue. Left lane: Pi M
(normal) individual. Note that variability of glycosylation
of the a1-antitrypsin results in isoforms of the M protein
having dierent isoelectric points, which cease migrating
at diering positions on the gel. The most prominent (M4
and M6) bands are marked. Center lane: Pi Z individual
with a1-antitrypsin deficiency. Note the fainter protein
bands that dier in isoelectric points. The corresponding
Z4 and Z6 bands are marked. Right lane: Pi MZ
heterozygote (carrier) for a1-antitrypsin deficiency. Note
the presence of both M and Z protein bands.
FIG. 2. Genotyping of a1-antitrypsin. Allele-specific primers, in a
specific size that depends upon the alleles that are present. The
shown when examined under ultraviolet light. Each panel show
amplifications are run for each analysis (A and B). The top an
products. The second band from the top relates to the Z allele
mutation, a band of that size amplifies in the A reaction. If the
reaction. Left panel, Pi MM (only the normal sequence); center p
Pi MZ (both the normal and the abnormal sequence).isoelectric focusing must be established with certainty, and
appropriate standards may or may not be available to all
diagnostic laboratories. Finally, the variants may or may
not dier in their isoelectric points, as is the case for the PiS
and PiV variants.
We have been interested in trying to improve the
objectivity of the interpretation of phenotyping gels. With
appropriate standards or a surface pH electrode, the
isoelectric points of the major isoforms of AAT can be
established with considerable precision. This observation
raises the possibility of interpreting isoelectric focusing gels
objectively, based on the measured isoelectric points of the
AAT protein. If validated by sequencing, new standards for
interpretation of phenotyping gels could be established.
Genotyping is the stage 3 method for the diagnosis of
AAT deficiency. Genotyping oers a very precise determi-
nation of an individual’s genetic makeup at the Pi locus,
based upon analysis of the individual’s DNA. We have
been involved in a very interesting and productive
collaboration with AstraZeneca that has taken advantage
of their ARMS technology for allele-specific polymerase
chain reaction. This technology amplifies a very large
number of copies of a nucleotide of a predetermined size if
the complementary DNA is present in an individual’s
genome. The process is precise enough that it will detect a
single base-pair substitution in the DNA. The ARMS
technology is robust and generally applicable to all point
mutations and small deletions. One of the strengths of the
technology is that it can accurately detect mutations even
when only trace amounts of DNA are present, which means
that one can use non-invasive samples, such as mouthwash
fluid or buccal scrapings as diagnostic specimens. Further-
more, it is possible to detect several mutations simulta-
neously and cost-eectively. The present/absent nature of
the products of the reaction make the technology an ideal
candidate for automation.
An example of an ARMS genotyping test is shown in
Fig. 2. The procedure shown is a straightforward simulta-
neous test for the Z mutation (the most common allelepolymerase chain reaction, are used to amplify products of
products are then run on an agarose gel to give the results
s the results from a single individual. Two dierent
d bottom bands in each lane are control amplification
in each lane. If the sequence is normal at the site of the Z
Z mutation is present, a band of that size amplifies in the B
anel, Pi ZZ (only the abnormal sequence); and right panel,
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common abnormal allele associated with much more mildly
reduced plasma AAT concentrations). A single ARMS
reaction can be designed to amplify products of various
sizes depending upon which mutation(s) are present in the
individual’s genome. We are currently working with
AstraZeneca to develop a multiplex test or tests for a
variety of other common mutations in the AAT gene. This
technology seems to be an ideal platform for expanding the
range of mutations in the AAT gene that can be detected
with a straightforward test procedure. An important
strength of genotyping is that it provides a definitive yes
or no answer for each mutation in the test. In addition to
the clinical value that this lends to testing, this yes/no
answer will lend itself well to automation. Because it is a
DNA-based test, genotyping can correctly identify muta-
tions that result in no detectable protein in plasma, and it
provides correct diagnoses in individuals who are receiving
augmentation therapy. Expense is a weakness of genotyp-
ing, depending upon the extent of testing that is necessary
to provide a correct diagnosis. It is generally not appro-
priate as a stand-alone test, although combining the
analysis with an immunoassay and phenotyping is appro-
priate in most cases. Genotypic diagnosis is not complete if
the procedure cannot identify both AAT alleles. In selected
cases when available primers fail to provide a complete
diagnosis, sequencing of exonic DNA is appropriate.
Functional measurement of a1-antitrypsin comprises the
stage 4 method of diagnostic testing. Rarely, mutations in
the a1-antitrypsin gene result in a protein with abnormal or
even altered function. There has been little experience with
large-scale application of these testing methods, which are
beyond the scope of this discussion.
The future: full-spectrum testing of
dried blood spots
In the 9 years that we have been testing for AAT deficiency,
our laboratory has been committed to finding improved
methods of testing for the disease. We have found that an
important barrier to widespread application of the WHO
recommendations for testing has been the inconvenience of
obtaining, packaging, and shipping liquid blood to a
central laboratory such as ours. Obtaining the blood
samples requires disposables and a skilled phlebotomist.
Shipping the potentially biohazardous specimens is costly
and requires biohazard packaging. We have developed
methods for full-spectrum AAT testing (Stages 1–4) thatcan be performed on a few drops of blood that have been
dried onto filter paper.
We have been involved in international collaborative
projects with Prof. Stockley in the U.K. and with Marion
Wencker in Germany, demonstrating that even interna-
tional shipment of dried blood spots provides samples that
are adequate for full-spectrum testing. We plan to make
testing of dried blood spots available in the U.S.A. in the
third quarter of 2000.
Summary and conclusions
Although certain diagnostic tests for a1-antitrypsin defi-
ciency have been available since the 1960s, most individuals
who have a1-antitrypsin deficiency world-wide escape
diagnosis. Undiagnosed individuals lose potentially life-
saving opportunities for lifestyle changes and medical
interventions. Identifying this large population of undiag-
nosed individuals will require improved awareness of a1-
antitrypsin deficiency and more convenient testing proce-
dures. Full-spectrum diagnostic testing of whole blood
dried onto filter paper is technically feasible and conve-
nient, and provides new possibilities for accomplishing the
wider testing for the disease that has been recommended by
the World Health Organization.
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